Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVR Anteris Technologies Global	$3.96 -1.7%	$4.29	$2.34 ▼ $8.79	$145.15M	N/A	223,861 shs	120,359 shs
CATX Perspective Therapeutics	$3.81 -0.3%	$2.75	$1.60 ▼ $16.55	$282.81M	1.09	1.09 million shs	1.38 million shs
DRTS Alpha Tau Medical	$2.99 +0.5%	$2.87	$1.75 ▼ $4.39	$209.03M	0.99	50,162 shs	16,532 shs
POSC Positron	$1.59 +3.2%	$1.57	$0.90 ▼ $2.94	$49.93M	0.45	7,220 shs	114 shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVR Anteris Technologies Global	-1.74%	-2.46%	+8.79%	-5.71%	+395,999,900.00%
CATX Perspective Therapeutics	-0.26%	+10.43%	+59.41%	+65.65%	-60.10%
DRTS Alpha Tau Medical	+0.51%	+2.58%	-0.50%	+12.22%	+38.19%
POSC Positron	0.00%	+1.27%	+0.63%	-10.17%	+22.31%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVR Anteris Technologies Global	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CATX Perspective Therapeutics	3.5987 of 5 stars	4.6	3.0	0.0	0.0	3.1	2.5	0.0
DRTS Alpha Tau Medical	2.7928 of 5 stars	3.5	5.0	0.0	0.0	0.0	1.7	0.0
POSC Positron	0.1513 of 5 stars	0.0	3.0	0.0	0.0	0.6	0.8	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVR Anteris Technologies Global	3.00	Buy	$16.50	316.67% Upside
CATX Perspective Therapeutics	3.18	Buy	$12.56	229.54% Upside
DRTS Alpha Tau Medical	3.00	Buy	$8.00	168.01% Upside
POSC Positron	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest POSC, DRTS, AVR, and CATX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/23/2025	CATX Perspective Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$9.00 ➝ $12.00
6/23/2025	CATX Perspective Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$11.00
6/3/2025	CATX Perspective Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform ➝ Moderate Buy	$15.00 ➝ $16.00
5/14/2025	CATX Perspective Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$10.00 ➝ $8.00
5/13/2025	CATX Perspective Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$11.00
4/29/2025	DRTS Alpha Tau Medical	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $9.00
4/7/2025	CATX Perspective Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$21.00 ➝ $10.00
3/31/2025	CATX Perspective Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
3/27/2025	CATX Perspective Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$16.00 ➝ $15.00
3/26/2025	CATX Perspective Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$11.00 ➝ $11.00

(Data available from 6/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVR Anteris Technologies Global	$2.70M	52.89	N/A	N/A	$1.74 per share	2.28
CATX Perspective Therapeutics	$1.43M	197.77	N/A	N/A	$2.67 per share	1.43
DRTS Alpha Tau Medical	N/A	N/A	N/A	N/A	$0.89 per share	N/A
POSC Positron	$590K	84.65	N/A	N/A	($0.04) per share	-39.75

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVR Anteris Technologies Global	-$76.29M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
CATX Perspective Therapeutics	-$46.51M	N/A	0.00	N/A	N/A	-4,096.66%	-27.40%	-23.16%	8/11/2025 (Estimated)
DRTS Alpha Tau Medical	-$31.75M	-$0.46	N/A	N/A	N/A	N/A	-49.48%	-36.69%	8/13/2025 (Estimated)
POSC Positron	-$2.39M	-$0.08	N/A	∞	N/A	-593.09%	N/A	-116.56%	N/A

Latest POSC, DRTS, AVR, and CATX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/19/2025	Q1 2025	DRTS Alpha Tau Medical	-$0.14	-$0.12	+$0.02	-$0.12	$0.03 million	N/A
5/15/2025	Q1 2025	POSC Positron	N/A	-$0.05	N/A	-$0.05	N/A	$0.12 million
5/13/2025	Q1 2025	AVR Anteris Technologies Global	N/A	-$0.61	N/A	-$0.61	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVR Anteris Technologies Global	N/A	N/A	N/A	N/A	N/A
CATX Perspective Therapeutics	N/A	N/A	N/A	N/A	N/A
DRTS Alpha Tau Medical	N/A	N/A	N/A	N/A	N/A
POSC Positron	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVR Anteris Technologies Global	N/A	3.67	3.65
CATX Perspective Therapeutics	N/A	9.60	9.60
DRTS Alpha Tau Medical	0.10	5.81	5.81
POSC Positron	N/A	2.69	2.04

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVR Anteris Technologies Global	N/A
CATX Perspective Therapeutics	54.66%
DRTS Alpha Tau Medical	2.65%
POSC Positron	N/A

Insider Ownership

Company	Insider Ownership
AVR Anteris Technologies Global	N/A
CATX Perspective Therapeutics	3.72%
DRTS Alpha Tau Medical	39.50%
POSC Positron	17.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVR Anteris Technologies Global	138	36.06 million	N/A	N/A
CATX Perspective Therapeutics	70	74.23 million	65.21 million	Optionable
DRTS Alpha Tau Medical	80	70.38 million	42.58 million	No Data
POSC Positron	20	31.41 million	26.00 million	Not Optionable

POSC, DRTS, AVR, and CATX Headlines

Recent News About These Companies

Positron (OTCMKTS:POSC) Shares Up 0.2% - Still a Buy?

June 11, 2025 | marketbeat.com

Positron Corporation Expands Market Presence with Sale of NeuSight PET-CT Scanner

May 29, 2025 | globenewswire.com

Positron Corporation Secures Agreement to Sell Four PET-CT Scanners

April 14, 2025 | globenewswire.com

Positron Corporation Secures $8 Million in Capital to Accelerate Growth and Market Expansion

March 31, 2025 | globenewswire.com

Positron Corporation Secures Agreement for Three NeuSight PET-CT 64 Slice Scanners

February 27, 2025 | globenewswire.com

Positron Corporation Announces Sale of Attrius PET and NeuSight PET-CT Scanners

January 28, 2025 | globenewswire.com

Positron Corporation Secures Agreement to Sell and Rent Eight NeuSight PET-CT Scanners

January 24, 2025 | globenewswire.com

Positron Corporation Engages Skyline Corporate Communications Group, LLC to Enhance Investor Relations and Financial Community Outreach

January 13, 2025 | globenewswire.com

Positron Corporation Partners With Upbeat Cardiology Solutions to Expand Cardiac PET-CT Offerings

November 21, 2024 | globenewswire.com

Positron Energy Ltd (POSITRON) Share Price

October 25, 2024 | businesstoday.inB

Positron Corporation Launches Prime Rental Program for Pet-Ct Systems

October 1, 2024 | globenewswire.com

Positron Corporation Announces Sale of NeuSight PET-CT Scanner

August 26, 2024 | globenewswire.com

Positron Corporation Introduces New, Advanced Designed, Economically Priced PET-CT

July 25, 2024 | globenewswire.com

Positron Corporation Orders 5 NeuSight PET-CT Scanners for US Market

June 26, 2024 | globenewswire.com

Positron Corporation Announces Attrius® PET System Sale

June 18, 2024 | globenewswire.com

Positron Corporation Joins Cardiac PET Industry Coalition (CPIC)

June 14, 2024 | globenewswire.com

Positron Corporation Enters OEM Supply and Distribution Agreement for NeuSight PET-CT 64 Slice Scanner

June 13, 2024 | globenewswire.com

Positron Corporation Enters Agreement to Acquire FDA 510(k) for NeuSight PET-CT

June 12, 2024 | globenewswire.com

Positron-Emission Tomography and Assessment of Cancer Therapy

December 22, 2023 | nejm.orgN

Positron Corporation Announces Attrius® PET System Sale

October 4, 2023 | finance.yahoo.com

Social Justice Minor and Course

September 11, 2023 | case.eduC

New MarketBeat Followers Over Time

Media Sentiment Over Time

POSC, DRTS, AVR, and CATX Company Descriptions

Anteris Technologies Global NASDAQ:AVR

$3.96 -0.07 (-1.74%)

As of 06/25/2025 04:00 PM Eastern

Anteris Technologies Global Corp. engages in the development and commercialization of medical devices for heart diseases. The company was founded in 1999 and is headquartered in Eagan, MN.

Perspective Therapeutics NYSE:CATX

$3.81 -0.01 (-0.26%)

Closing price 06/25/2025 04:00 PM Eastern

Extended Trading

$3.84 +0.03 (+0.81%)

As of 06/25/2025 07:54 PM Eastern

Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.

Alpha Tau Medical NASDAQ:DRTS

$2.98 +0.02 (+0.51%)

As of 06/25/2025 03:58 PM Eastern

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.

Positron OTCMKTS:POSC

$1.59 +0.05 (+3.25%)

As of 06/24/2025 11:25 AM Eastern

Positron Corporation, a nuclear medicine healthcare company, specializes in the business of cardiac positron emission tomography (PET) imaging in the United States. It offers attrius PET scanner, clinical and technical services, and financing solutions enables healthcare providers to accurately diagnose cardiac disease, improve patient outcomes, and practice cost effective medicines. Positron Corporation was incorporated in 1983 and is based in Niagara Falls, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time